Sanofi (SNY)

Sanofi is a global healthcare company focused on pharmaceuticals, vaccines, and consumer healthcare. With a diverse portfolio and a strong pipeline, Sanofi addresses significant health needs worldwide.

50/100 AI Score MCap 116B Vol 5M

Company Overview

CEOPaul Hudson
Employees82878
HeadquartersParis, FR
IPO Year2002

Sanofi (SNY) is a global healthcare leader with a diversified portfolio spanning pharmaceuticals, vaccines, and consumer health, offering investors a compelling opportunity to capitalize on innovative therapies and a robust 4.88% dividend yield in a stable, yet growing market.

Investment Thesis

Sanofi presents a compelling investment opportunity due to its diversified revenue streams across pharmaceuticals, vaccines, and consumer healthcare. The company's robust pipeline of innovative therapies and vaccines, coupled with strategic collaborations, positions it for sustained growth. Sanofi's attractive 4.88% dividend yield offers investors a steady income stream. With a P/E ratio of 12.61 and a profit margin of 17.9%, Sanofi demonstrates financial stability and profitability. Key value drivers include successful drug launches, expansion in emerging markets, and continued innovation in its core therapeutic areas. The company's low beta of 0.37 suggests lower volatility compared to the broader market, making it an attractive option for risk-averse investors.

Key Highlights

  • Market Cap of $116.17B indicates Sanofi's significant size and stability within the pharmaceutical industry.
  • P/E Ratio of 12.61 suggests that the company is reasonably valued compared to its earnings.
  • Profit Margin of 17.9% demonstrates strong profitability and efficient operations.
  • Gross Margin of 70.1% reflects Sanofi's ability to generate substantial revenue from its products after accounting for the cost of goods sold.
  • Dividend Yield of 4.88% provides an attractive income stream for investors, highlighting the company's commitment to returning value to shareholders.

Competitors

Strengths

  • Diversified product portfolio across pharmaceuticals, vaccines, and consumer healthcare.
  • Strong global presence and established distribution network.
  • Robust research and development capabilities.
  • High gross margin of 70.1%.

Weaknesses

  • Dependence on key products and patent expirations.
  • Exposure to regulatory risks and pricing pressures.
  • Potential for product recalls and liability claims.
  • Competition from generic drug manufacturers.

Catalysts

  • Upcoming: Results from key clinical trials for novel therapies in oncology and immunology.
  • Ongoing: Expansion of vaccine portfolio through research and development.
  • Ongoing: Strategic partnerships and acquisitions to enhance product offerings.
  • Ongoing: Growth in emerging markets driven by increasing healthcare spending.

Risks

  • Potential: Patent expirations on key products leading to generic competition.
  • Potential: Regulatory setbacks and delays in drug approvals.
  • Potential: Product liability claims and recalls.
  • Ongoing: Pricing pressures and reimbursement challenges from healthcare payers.
  • Ongoing: Competition from other pharmaceutical companies.

Growth Opportunities

  • Expansion in Emerging Markets: Sanofi has a significant opportunity to expand its presence in emerging markets, such as China and India, where healthcare spending is rapidly increasing. These markets offer a large and growing patient population, creating demand for Sanofi's pharmaceutical products and vaccines. By establishing strategic partnerships and tailoring its product offerings to local needs, Sanofi can capitalize on the growth potential in these regions. This expansion could contribute significantly to revenue growth over the next 3-5 years.
  • Development of Novel Therapies: Sanofi's robust research and development pipeline presents a significant growth opportunity. The company is investing in the development of novel therapies for various diseases, including oncology, immunology, and rare diseases. Successful development and commercialization of these therapies could generate substantial revenue and enhance Sanofi's competitive position. The timeline for these developments varies, but several key clinical trials are expected to yield results in the next 2-3 years.
  • Strategic Acquisitions and Partnerships: Sanofi can drive growth through strategic acquisitions and partnerships with other companies in the healthcare sector. By acquiring companies with complementary technologies or product portfolios, Sanofi can expand its capabilities and market reach. Partnerships can also provide access to new markets and technologies. These strategic moves can accelerate Sanofi's growth and enhance its long-term value. The company is actively exploring potential acquisition targets and partnership opportunities.
  • Growth in Vaccine Segment: The global vaccine market is experiencing significant growth, driven by increasing awareness of the importance of immunization and the emergence of new infectious diseases. Sanofi, with its established vaccine portfolio, is well-positioned to capitalize on this trend. By developing and commercializing new vaccines, Sanofi can expand its market share and contribute to global health. The company is investing in research and development of vaccines for various diseases, including respiratory syncytial virus (RSV) and influenza.
  • Consumer Healthcare Expansion: Sanofi's Consumer Healthcare segment offers a stable and growing revenue stream. The company can further expand this segment by launching new over-the-counter products and expanding its distribution channels. The consumer healthcare market is driven by factors such as self-medication trends and an aging population. By focusing on innovative products and effective marketing strategies, Sanofi can increase its market share and drive growth in this segment. The company plans to launch several new consumer healthcare products in the next 1-2 years.

Opportunities

  • Expansion in emerging markets with growing healthcare spending.
  • Development and commercialization of novel therapies.
  • Strategic acquisitions and partnerships to expand product portfolio.
  • Growth in the vaccine market due to increasing awareness of immunization.

Threats

  • Increasing competition from other pharmaceutical companies.
  • Pricing pressures and reimbursement challenges.
  • Regulatory changes and stricter approval processes.
  • Economic downturns and healthcare budget cuts.

Competitive Advantages

  • Strong brand recognition and reputation in the healthcare industry.
  • Extensive research and development capabilities.
  • Diversified product portfolio across pharmaceuticals, vaccines, and consumer healthcare.
  • Global presence and established distribution network.
  • Intellectual property protection for key products.

About

Founded in 1973 and headquartered in Paris, France, Sanofi has evolved into a global healthcare giant. Originally known as Sanofi-Aventis, the company rebranded in 2011 to reflect its broader focus and strategic vision. Sanofi operates through three primary segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and markets specialty care products, including human monoclonal antibodies and treatments for multiple sclerosis, neurology, immunology, oncology, and rare diseases. The Vaccines segment provides a range of pediatric and adult vaccines, including those for poliomyelitis, influenza, and meningitis. The Consumer Healthcare segment offers over-the-counter products for allergies, cough and cold, pain relief, and digestive health. Sanofi's global presence extends across the United States, Europe, and other international markets. The company has strategic collaborations with organizations like GlaxoSmithKline and Stanford University School of Medicine to enhance its research and development efforts. With a workforce of over 82,000 employees, Sanofi is committed to advancing healthcare solutions and improving patient outcomes worldwide.

What They Do

  • Researches and develops pharmaceutical products.
  • Manufactures and markets therapeutic solutions.
  • Offers a range of vaccines for various diseases.
  • Provides consumer healthcare products for allergies, pain relief, and digestive health.
  • Develops specialty care products, including monoclonal antibodies.
  • Offers treatments for multiple sclerosis, neurology, and immunology.
  • Provides medicines for diabetes and cardiovascular diseases.

Business Model

  • Develops and commercializes pharmaceutical products, vaccines, and consumer healthcare products.
  • Generates revenue through sales of its products to healthcare providers, pharmacies, and consumers.
  • Invests heavily in research and development to discover and develop new therapies and vaccines.
  • Forms strategic partnerships and collaborations to expand its product portfolio and market reach.

Industry Context

Sanofi operates in the global pharmaceutical industry, a sector characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and technological advancements in drug discovery. Sanofi competes with other major pharmaceutical companies, including Amgen (AMGN) and Bristol-Myers Squibb (BMY). The industry is witnessing a shift towards personalized medicine and innovative therapies, creating opportunities for companies like Sanofi to leverage their research capabilities and pipeline of novel products. The global pharmaceuticals market is projected to reach trillions of dollars in the coming years, offering substantial growth potential for well-positioned players.

Key Customers

  • Healthcare providers, including hospitals and clinics.
  • Pharmacies and retail stores.
  • Patients who use Sanofi's pharmaceutical and consumer healthcare products.
  • Government agencies and public health organizations that purchase vaccines.
AI Confidence: 73% Updated: 2/8/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q3 2024 $12.98B $2.81B $1.12
Q4 2024 $7.63B $499M $0.20
Q1 2025 $10.61B $1.87B $0.76
Q2 2025 $10.73B $3.94B $0.00

Source: Company filings

Chart & Info

Price Chart

Sanofi (SNY) stock price: $47.51 (-0.72, -1.49%)

Latest News

Technical Analysis

bearish Trend
RSI(14)
48.5
MACD
--
Volume
4,256,215

Rationale

AI-generated technical analysis for SNY including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss Sanofi (SNY) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for SNY.

Make a Prediction

Set your price target for Sanofi (SNY), choose a timeframe, and track your prediction accuracy.

Current price: $47.51

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SNY.

Price Targets

Low
$48.07
Consensus
$57.02
High
$64.00

Median: $58.00 (+20.0% from current price)

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

49.5/100

Score Factors

  • Revenue Growth 4/100

    Revenue grew only 6.2% YoY, suggesting the company is in a slower growth phase.

  • Gross Margin 10/100

    Gross margin of 71.7% shows excellent pricing power and a strong competitive moat.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 7/100

    Lower turnover at 0.23% means fewer daily trades, which may widen bid-ask spreads.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates SNY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Sanofi do?

Sanofi is a global healthcare company that discovers, develops, manufactures, and markets a wide range of pharmaceutical products, vaccines, and consumer healthcare products. The company operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Sanofi's pharmaceutical products include specialty care treatments for diseases such as multiple sclerosis, oncology, and immunology. Its vaccine segment provides vaccines for various infectious diseases, while its consumer healthcare segment offers over-the-counter products for allergies, pain relief, and digestive health. Sanofi's diverse portfolio and global presence position it as a key player in the healthcare industry.

Is SNY stock a good buy?

SNY stock presents a mixed outlook. The company's diversified business model, strong dividend yield of 4.88%, and robust pipeline of new therapies are positive factors. Sanofi's P/E ratio of 12.61 suggests reasonable valuation. However, potential risks include patent expirations, regulatory challenges, and competition from other pharmaceutical companies. Investors should carefully consider these factors and their own risk tolerance before investing in SNY. A balanced approach considering both growth potential and inherent risks is essential for making an informed investment decision.

What are the main risks for SNY?

Sanofi faces several key risks, including patent expirations on key products, which could lead to generic competition and reduced revenue. Regulatory challenges and delays in drug approvals pose another significant risk, as they can impact the company's ability to bring new products to market. Product liability claims and recalls can also negatively affect Sanofi's financial performance and reputation. Furthermore, pricing pressures and reimbursement challenges from healthcare payers could limit the company's ability to generate revenue from its products. Intense competition from other pharmaceutical companies is an ongoing risk that requires Sanofi to continuously innovate and differentiate its offerings.

Is SNY a good stock to buy?

Whether SNY is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the SNY MoonshotScore?

The MoonshotScore for SNY is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is SNY data updated?

SNY stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to SNY is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for SNY?

Growth catalysts for Sanofi (SNY) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Sanofi's specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are SNY's main competitors?

Sanofi (SNY) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether SNY has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about SNY?

Wall Street analyst coverage for SNY includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is SNY's market cap?

Market capitalization (market cap) for SNY is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows SNY's current market cap alongside enterprise value and other valuation metrics.

How has SNY stock performed recently?

SNY's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing SNY's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in SNY?

Key risk categories for SNY include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures SNY's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling SNY?

Insider trading activity for SNY tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is SNY a good stock for beginners?

Sanofi (SNY) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is SNY for first-time investors?

Every stock carries risk, including Sanofi (SNY). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like SNY.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Information is based on available data and may be subject to change.
  • Investment decisions should be based on individual risk tolerance and financial circumstances.
Data Sources
profilefundamentalsexistingCopy